GlassScriptPhysician profile
Amy E Kuruvilla
NPI 1366976508
$1,057.61
in general payments reported to CMS, 2019-2025
14 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.85 · 2023: $290 · 2024: $255 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $217.44 | 2022-2025 | Rexulti |
| Lundbeck LLC | $182.64 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $170.56 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $128.09 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $85.62 | 2023-2024 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $78.24 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $38.69 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $35.68 | 2025 | Cologuard Collection Kit |
| Philips North America LLC | $27.46 | 2025 | Extended Holter |
| Scpharmaceuticals INC. | $25.85 | 2025 | |
| Abbvie INC. | $23.38 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $20.56 | 2024 | Fasenra |
| E.R. Squibb & Sons, L.L.C. | $14.75 | 2025 | Eliquis |
| Dynavax Technologies Corporation | $8.65 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Kuruvilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.